Sei Investments Co. Has $6.15 Million Stake in Artivion, Inc. $AORT

Sei Investments Co. boosted its position in shares of Artivion, Inc. (NYSE:AORT) by 47.0% during the 1st quarter, HoldingsChannel.com reports. The fund owned 168,012 shares of the company’s stock after buying an additional 53,728 shares during the quarter. Sei Investments Co.’s holdings in Artivion were worth $6,153,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Morgan Stanley lifted its stake in Artivion by 0.8% in the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after purchasing an additional 18,248 shares during the last quarter. State Street Corp grew its holdings in Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after purchasing an additional 44,641 shares during the period. Fred Alger Management LLC grew its holdings in Artivion by 4.2% during the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares during the period. Finally, Conestoga Capital Advisors LLC acquired a new position in Artivion during the first quarter worth approximately $43,044,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Up 2.7%

Artivion stock opened at $27.54 on Tuesday. The company’s 50-day moving average price is $23.20 and its two-hundred day moving average price is $31.51. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The stock has a market cap of $1.34 billion, a P/E ratio of 114.76 and a beta of 1.24. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on AORT shares. Canaccord Genuity Group restated a “buy” rating and issued a $36.00 price objective on shares of Artivion in a research note on Tuesday, June 16th. Stifel Nicolaus set a $45.00 target price on Artivion in a report on Monday, June 1st. Citizens Jmp dropped their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Finally, Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Artivion has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.